Allergan has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for Truberzi (eluxadoline), an oral medication for treating irritable bowel syndrome with diarrhea in adults.

The final decision from the European Commission, which gives marketing authorization for medicines across the 28 member states of the European Union, is expected within a few months of July. If approved, Allergan anticipates launching the new product in Europe during 2017, pending negotiations with the relevant national payer and reimbursement groups.

Source: Allergan